Close

Bora Pharmaceuticals is Awarded Outstanding Company of the Year at Bio-Asia Taiwan 2023

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

July 27, 2023

Bio-Asia Taiwan Exhibition

Taipei, Taiwan

Bora has been awarded “Outstanding Company of the Year” by an independent panel of international judges during Bio-Asia Taiwan exhibit taking place in Taipei, Taiwan July 24-26, 2023. Bora was chosen from a short list of several candidates for its demonstrated leadership in the Taiwan Biopharma industry.

Bobby Sheng said; “Our team’s focused dedication to excellence in quality and customer service continues to be acknowledged by our clients and in BioPharma industry. I’m especially proud of our biologic subsidiary, Bora Biologics, for growing at such a rapid pace and being recognized in the Biopharma community.” 

Bora is currently the only CDMO in Taiwan that has a leading position in both small and large molecules with 6 manufacturing sites with over 70 Billion NTD market cap.

https://boracdmo.com/news-and-events/bora-pharmaceuticals-is-awarded-outstanding-company-of-the-year-at-bio-asia-taiwan-2023/

Company: BORA PHARMACEUTICAL SERVICES INC.


Bora Pharmaceuticals and our group of companies is a publicly-traded company on the Taiwan Stock Exchange (6472). We are Taiwan's largest CDMO with a 50-year history in the Pharmaceutical Industry. We supply drugs to over 100 countries in the world, including the US/Canada, EU, Southeast Asia, Middle East, and South and Central America. We provide outsourced R&D, CDMO, and CMO services for global pharmaceutical companies around the world.

Send Enquiry for this story

By submitting this form you are giving a consent to Worldpharmatoday.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.

Latest stories